[A21-85] Beclometasone/formoterol/glycopyrronium (asthma) - Addendum to Commission A21-18

Last updated 05.08.2021

Project no.:

Commission awarded on 22.06.2021 by the Federal Joint Committee (G-BA).

Report type:

Commission completed

Drug Assessment

Application field:
Airways and respiratory system


Adult patients with asthma whose disease is not adequately controlled with a combination of medium- or high-dose ICS and LABA, and who experienced one or more asthma exacerbations in the previous year

Result of dossier assessment:

Unchanged after addendum:

  • Medium-dose ICS/LABA therapy: added benefit not proven.
  • High-dose ICS/LABA therapy: added benefit not proven.

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Federal Joint Committee (G-BA)

2021-08-05: A G-BA decision was published.

G-BA documents on this decision


Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form